Madrigal Pharmaceuticals (MDGL) announced it has appointed Jacqualyn Fouse, Ph.D. to its Board of Directors. Fred Craves, Ph.D. is retiring from the Board in July 2025.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MDGL:
- Goldman Sachs Says It’s Time to Pull the Trigger on Healthcare Stocks — Here Are 2 Names to Pounce on Now
- Biotech Alert: Searches spiking for these stocks today
- Madrigal’s Earnings Call Highlights Strong Growth
- Madrigal Pharmaceuticals price target raised to $239 from $154 at BofA
- Nvidia, Constellation Brands downgraded: Wall Street’s top analyst calls